GLP-1 receptor agonist treatment in women with polycystic ovary syndrome—a systematic review and meta-analysis
Pooled result · BMIResult — go to the resultMD −1.38 kg/m² 95% CI −2.39 to −0.38Authors' conclusion
GLP-1-RAs are associated with modest short-term weight loss in women with PCOS and overweight or obesity. Evidence for benefits on metabolic, reproductive, or psychological outcomes remains uncertain due to low-quality data, and no studies have evaluated cost-effectiveness.
Study context
- Population
- Women with polycystic ovary syndrome (PCOS) (overweight or obesity)11 randomized controlled trials (RCTs)
- Comparison
- GLP-1 RA vs no treatment, placebo, lifestyle intervention, combined oral contraceptives, antiandrogenic drugs or metformin
- Outcome
- BMI
Methodological detailsCochrane Library, EMBASE and Medline searched September 20, 2024; 9654 studies identified, 365 read in full text
- Cochrane Library, EMBASE and Medline searched September 20, 2024; 9654 studies identified, 365 read in full text
Pooled result
As reported in the abstract
MD
−1.38 kg/m²
95% CI −2.39 to −0.38
GLP1-RAsvs Control
MD −1.38 kg/m² (95% CI −2.39 to −0.38)
Further pooled results
LDL-C and TG
- No difference between the groups
- Low certainty
Glucose, insulin, hirsutism, menstrual regularity
- Evidence insufficient to draw conclusion
Quality of life, mental health, cost-effectiveness
- No studies identified
Original publication
GLP-1 receptor agonist treatment in women with polycystic ovary syndrome—a systematic review and meta-analysis. Eur J Endocrinol. Published 17 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →